The Latest Cardiac and Vascular News
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients March 04, 2025 08:00 AM Eastern Standard Time PONTE VEDRA, Fla.–(BUSINESS WIRE)–Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with […]
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]
– Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD) – Access to MCS devices are critical for advanced heart failure patients and can improve […]
– Abbott’s HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure – This life-saving technology provides new treatment option for underserved population ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the […]
Orlando, Fla., April 04, 2019 (GLOBE NEWSWIRE) — Patients with a newer version of a common heart pump experienced a reduced aggregate burden of bleeding and stroke rates – and no pump thrombosis requiring surgical exchange, compared to patients with the predecessor device. The MOMENTUM3 study was a randomized controlled […]
NEW ORLEANS, March 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world’s largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint […]
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not […]
ORLANDO, Fla., March 11, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device (LVAD) trial in the world to evaluate patients in need of both short-term and long-term support in a single study. The data were published online […]
